Document:

exv4w1

EXHIBIT 4.1

FIFTH AMENDMENT

TO

RIGHTS AGREEMENT

THIS FIFTH AMENDMENT TO RIGHTS AGREEMENT (this “Amendment”) is made as of May 23, 2011 by and
between The Allied Defense Group, Inc., a Delaware corporation (the “Company”), and Mellon Investor
Services LLC, a New Jersey limited liability company (the “Rights Agent”).

WHEREAS, the Company and the Rights Agent are parties to that certain Rights Agreement dated
as of June 6, 2001, as amended by that certain First Amendment to Rights Agreement dated as of June
15, 2006, as further amended by that certain Second Amendment to Rights Agreement dated as of
November 30, 2006, as further amended by that certain Third Amendment to Rights Agreement dated as
of January 18, 2010 and as further amended by that certain Fourth Amendment to Rights Agreement
dated as of June 24, 2010 (collectively, the “Current Rights Agreement”);

WHEREAS, Section 26 of the Current Rights Agreement provides, in part, that for so long as the
Rights (as defined in the Current Rights Agreement) are redeemable, the Current Rights Agreement
may be supplemented or amended without the approval of holders of the Rights;

WHEREAS, the Rights are currently redeemable; and

WHEREAS, the Board of Directors of the Company has determined in good faith that the amendment
to the Current Rights Agreement set forth herein is desirable and, pursuant to Section 26 of the
Current Rights Agreement, has duly authorized such amendment to the Current Rights Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Company and the Rights Agent hereby agree as follows:

1. DEFINITIONS. Except as otherwise set forth in this Amendment, each capitalized term used
in this Amendment shall have the meaning for such term set forth in the Current Rights Agreement.

2. DEFINITION OF EXPIRATION DATE. Section 1(s) of the Current Rights Agreement is hereby
amended by deleting the reference therein to “May 31, 2011” and replacing it with “December 31,
2011”.

3. COUNTERPARTS. This Amendment may be executed in counterparts, each of which shall
constitute an original and all of which together shall constitute but one original; provided,
however, this Amendment shall not be effective unless and until signed by the Company and the
Rights Agent.

 

1

 

4. GOVERNING LAW. This Amendment shall be deemed to be a contract made under the laws of
the State of Delaware and for all purposes shall be governed by and construed in accordance with
the internal laws of the State of Delaware applicable to contracts to be made and performed
entirely within the State of Delaware; provided, however, that all provisions
regarding the rights, duties and obligations of the Rights Agent shall be governed by and construed
in accordance with the laws of the State of New York applicable to contracts made and to be
performed entirely within such State.

5. SEVERABILITY. If any term, provision, covenant or restriction of this Amendment is held
by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in
full force and effect and shall in no way be affected, impaired or invalidated.

6. EFFECTIVE DATE. This Amendment shall become effective as of the date first written
above.

7. CERTIFICATION. The Company hereby certifies to the Rights Agent that this Amendment is
in compliance with Section 26 of the Current Rights Agreement.

8. FULL FORCE AND EFFECT. The Current Rights Agreement, as amended by this Amendment, shall
remain in full force and effect in accordance with its terms. In the event of any conflict,
inconsistency or incongruity between any provision of this Amendment and any provision of the
Current Rights Agreement, the provisions of this Amendment shall govern and control.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of
the date set forth above.

	 	 	 	 	 	 	 
	THE ALLIED DEFENSE GROUP, INC.	 	MELLON INVESTOR SERVICES LLC,

as Rights Agent
	 
	 	 	 	 	 	 
	By:

	 	/s/ John G. Meyer, Jr.
	 	By:
	 	/s/ Casandra Shedd
	 

	 	 
	 	 	 	 
	 

	 	John G. Meyer, Jr., President
	 	 	 	CassandraShedd, Relationship Manager

 

2exv4w6

EXHIBIT 4.6

FIFTH AMENDMENT

TO

RIGHTS AGREEMENT

THIS FIFTH AMENDMENT TO RIGHTS AGREEMENT (this “Amendment”) is made as of May 23, 2011 by and
between The Allied Defense Group, Inc., a Delaware corporation (the “Company”), and Mellon Investor
Services LLC, a New Jersey limited liability company (the “Rights Agent”).

WHEREAS, the Company and the Rights Agent are parties to that certain Rights Agreement dated
as of June 6, 2001, as amended by that certain First Amendment to Rights Agreement dated as of June
15, 2006, as further amended by that certain Second Amendment to Rights Agreement dated as of
November 30, 2006, as further amended by that certain Third Amendment to Rights Agreement dated as
of January 18, 2010 and as further amended by that certain Fourth Amendment to Rights Agreement
dated as of June 24, 2010 (collectively, the “Current Rights Agreement”);

WHEREAS, Section 26 of the Current Rights Agreement provides, in part, that for so long as the
Rights (as defined in the Current Rights Agreement) are redeemable, the Current Rights Agreement
may be supplemented or amended without the approval of holders of the Rights;

WHEREAS, the Rights are currently redeemable; and

WHEREAS, the Board of Directors of the Company has determined in good faith that the amendment
to the Current Rights Agreement set forth herein is desirable and, pursuant to Section 26 of the
Current Rights Agreement, has duly authorized such amendment to the Current Rights Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Company and the Rights Agent hereby agree as follows:

1. DEFINITIONS. Except as otherwise set forth in this Amendment, each capitalized term used
in this Amendment shall have the meaning for such term set forth in the Current Rights Agreement.

2. DEFINITION OF EXPIRATION DATE. Section 1(s) of the Current Rights Agreement is hereby
amended by deleting the reference therein to “May 31, 2011” and replacing it with “December 31,
2011”.

3. COUNTERPARTS. This Amendment may be executed in counterparts, each of which shall
constitute an original and all of which together shall constitute but one original;
provided, however, this Amendment shall not be effective unless and until signed by the
Company and the Rights Agent.

 

1

 

4. GOVERNING LAW. This Amendment shall be deemed to be a contract made under the laws of
the State of Delaware and for all purposes shall be governed by and construed in accordance with
the internal laws of the State of Delaware applicable to contracts to be made and performed
entirely within the State of Delaware; provided, however, that all provisions
regarding the rights, duties and obligations of the Rights Agent shall be governed by and construed
in accordance with the laws of the State of New York applicable to contracts made and to be
performed entirely within such State.

5. SEVERABILITY. If any term, provision, covenant or restriction of this Amendment is held
by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in
full force and effect and shall in no way be affected, impaired or invalidated.

6. EFFECTIVE DATE. This Amendment shall become effective as of the date first written
above.

7. CERTIFICATION. The Company hereby certifies to the Rights Agent that this Amendment is
in compliance with Section 26 of the Current Rights Agreement.

8. FULL FORCE AND EFFECT. The Current Rights Agreement, as amended by this Amendment, shall
remain in full force and effect in accordance with its terms. In the event of any conflict,
inconsistency or incongruity between any provision of this Amendment and any provision of the
Current Rights Agreement, the provisions of this Amendment shall govern and control.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of
the date set forth above.

	 	 	 	 	 	 	 
	THE ALLIED DEFENSE GROUP, INC.	 	MELLON INVESTOR SERVICES LLC,

as Rights Agent
	 
	 	 	 	 	 	 
	By:

	 	/s/ John G. Meyer, Jr.
	 	By:
	 	/s/ Casandra Shedd
	 

	 	 
	 	 	 	 
	 

	 	John G. Meyer, Jr., President
	 	 	 	Cassandra Shedd, Relationship Manager

 

2exv10w1

Exhibit 10.1

	 	 	 
	

	 	BioCryst Pharmaceuticals, Inc.

4505 Emperor Blvd, Suite 200

Durham, NC 27703

919-859-1302 phone

919-859-1314 fax

www.biocryst.com

May 23, 2011

Mr. Thomas R. Staab II, CPA

520 Tharps Lane

Raleigh, NC 27614

Dear Mr. Staab:

     On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst” or the
“Company”), we are very excited to offer you the position of Senior Vice President and Chief
Financial Officer. We, along with the other members of the Company’s Board of Directors (the
“Board”), and the Company’s management team, are all very impressed with you and what you will
bring to the Company. We believe that with your background, you will make significant
contributions to the success of the Company.

     This letter agreement (the “Agreement”) will serve to confirm our agreement with respect to
the terms and conditions of your employment.

1. Term of Employment. Subject to the terms and conditions of this Agreement, BioCryst hereby
employs Thomas R. Staab (the “Employee”), effective July 1st, 2011, as Senior Vice
President and Chief Financial Officer of BioCryst, and Employee hereby accepts such employment.
Employee shall commence employment at the Company’s Durham, North Carolina office. The Employee
shall not, during the term of his employment, engage in any other business activity that would
interfere with, or prevent him from carrying out, his duties and responsibilities under this
Agreement. BioCryst hereby agrees and acknowledges that any compensation which the Employee
receives from participation in such allowable activities shall be outside the scope of this
Agreement and in addition to any compensation received hereunder. The term of employment of
Employee under this Agreement shall commence as of July 1st, 2011, and shall terminate
on June 30, 2015 unless earlier terminated in accordance with the provisions of paragraph 4 hereof.
In the event Employee is retained by the Company as Senior Vice President and Chief Financial
Officer past June 30, 2015, the terms of his employment shall continue to be governed by this
Agreement unless otherwise provided by the Board.

 

 

2. Basic Full-Time Compensation and Benefits.

     (a) As basic compensation for services rendered under this Agreement, Employee shall be
entitled to receive from BioCryst, a salary of $30,800.33 per month ($370,000 per annum)
payable in bi-monthly payments for each calendar month during the term of this Agreement,
beginning July 1, 2011. This salary will be reviewed annually by the Board of Directors and
may be raised at the discretion of the Board.

     (b) In addition to the basic compensation set forth in (a) above, Employee shall be
eligible to earn a cash bonus, payable as soon as reasonably practicable in the calendar
year following each calendar year during the term of this Agreement, based on the Company’s
achievement of performance related goals proposed by management and approved by the Board
for the Company’s applicable fiscal year (the “Fiscal Year”). The bonus actually earned, if
any, shall be based on a target amount equal to 30% of the base compensation earned by
executive during such Fiscal Year (the “Target Amount”), and shall be pro-rated based on the
degree to which the performance goals have been achieved, subject to a minimum level of
achievement proposed by management and approved by the Board. The Target Amount for the
2011 Fiscal Year shall be prorated based on Employee’s base compensation earned during 2011.
The Board may, in its discretion, approve a bonus in excess of the Target Amount if the
performance goals have been exceeded. Employee must be employed through April 1, of the
next succeeding Fiscal Year in order to receive the annual bonus for each Fiscal Year.

     (c) In addition to the basic compensation set forth in (a) and (b) above, Employee
shall be entitled to receive such other benefits and perquisites provided to other executive
officers of BioCryst which benefits may include, without limitation, reasonable vacation
(currently 4 weeks), sick leave, medical benefits, life insurance, and participation in
profit sharing or retirement plans.

     (d) In addition to the compensation set forth in paragraphs 2(a), (b) and (c) above,
the Board of Directors of BioCryst may from time to time, in its discretion, also grant such
other cash or stock bonuses to the Employee either as an award or as an incentive as it
shall deem desirable or appropriate.

3. Initial Equity Awards. In connection with Employee’s execution of this Agreement, Employee shall
be issued initial equity incentive awards as follows:

     (a) The Company shall grant to Employee an option to purchase 200,000 shares of the
Company’s common stock (“Common Stock”), with an exercise price equal to the fair market
value of the Common Stock on the date of the grant, which option shall vest and become
exercisable in accordance with paragraph 3(d) below. The option will be an “incentive stock
option” up to the maximum number of shares that may be covered under an incentive stock
option pursuant to the tax code.

     (b) The award set forth in paragraph 3(a) above will vest, contingent on Employee’s
continued provision of services to the Company on each respective vesting date, over a
period of 4 years as follows: The Option will initially become exercisable for 25% of the
Optioned Shares upon Optionee’s completion of twelve (12) months of Service (as defined in
the Standard Stock Option Agreement) measured from the Grant Date and will become
exercisable for the balance of the Optioned Shares at the rate of 25% of the Optioned Shares
upon

 

 

Optionee’s completion of each additional year of Service measured from the first
anniversary of the Grant Date for the following three years until fully vested on the fourth
anniversary of the grant.

     (c) The Company shall grant to Employee 25,000 restricted shares of the Company’s
Common Stock, as described and granted pursuant to the BioCryst Pharmaceuticals, Inc., Stock
Incentive Plan. Subject to Employee’s continuous employment with or service to the Company
from the date of grant thru the Vesting Date (12 months from date of hire), the transfer
restrictions on the restricted shares shall lapse and the restricted shares shall vest and
no longer be subject to forfeiture.

     (d) The stock option awards set forth in paragraph 3(a & c) above shall be granted
under and subject to the terms of the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan
(the “Stock Incentive Plan”). All awards shall be subject to the terms of specific award
agreements between the Employee and the Company, which Employee will be required to execute
as a condition of the grants.

4. Termination.

     (a) If Employee’s employment is terminated as a result of (i) the expiration of the
stated term of this Agreement, (ii) the Employee’s resignation, (iii) the Employee’s death,
(iv) by the Company for Cause, or (v) by the Company as a result of Disability, Employee
will receive base salary, as well as any accrued but unused vacation (if applicable) and
other compensation, earned through the effective termination date, and no additional
compensation, except as set forth in Section 4(d) below.

     For all purposes under this Agreement, a termination for “Cause” shall mean a
determination by the Board that Employee’s employment be terminated for any of the following
reasons: (i) failure or refusal to comply in any material respect with lawful policies,
standards or regulations of Company; (ii) a violation of a federal or state law or
regulation applicable to the business of the Company; (iii) conviction or plea of no contest
to a felony under the laws of the United States or any State; (iv) fraud or misappropriation
of property belonging to the Company or its affiliates; (v) a breach in any material respect
of the terms of any confidentiality, invention assignment or proprietary information
agreement with the Company or with a former employer, (vi) failure to satisfactorily
perform Employee’s duties after having received written notice of such failure and at least
thirty (30) days to cure such failure, or (vii) misconduct or gross negligence in connection
with the performance of Employee’s duties.

     “Disability” shall mean the inability of Employee to perform his duties hereunder by
reason of physical or mental incapacity for ninety (90) days, whether consecutive or not,
during any consecutive twelve (12) month period.

     (b) If the Company terminates Employee’s employment without Cause, it shall provide
written notice of termination to Employee, along with any base salary and accrued but unused
vacation or other compensation earned through the effective termination date, and,
conditioned on Employee (a) signing and not revoking a release of any and all claims, in a
form prescribed by the Company, and (b) returning to the Company all of its property and
confidential information that is in Employee’s possession, Employee will receive the
following: (i) continuation of base salary for 1 year beyond the effective termination
date, payable in

 

 

accordance with the regular payroll practices of the Company; (ii) payment of
Employee’s target bonus in effect for the fiscal year of termination, payable in equal
installments over the regularly scheduled payroll periods of the Company for the one year
following the effective date of termination; and (iii) if Employee elects to continue health
insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended (“COBRA”) following termination of employment, the Company shall pay the monthly
premium under COBRA until the earlier of (x) 6 months following the effective termination
date, or (y) the date upon which Employee commences employment with an entity other than the
Company. Employee will notify the Company in writing within 5 days of your receipt of an
offer of employment with any entity other than the Company, and will accordingly identify
the date upon which you will commence employment in such writing.

     (c) If, during Employee’s employment with the Company, there is a Change of Control,
all equity awards granted to Employee under paragraph 3 and otherwise shall vest in full.
In addition, if the Company terminates Employee’s employment without Cause or Employee is
Constructively Terminated within 6 months of the Change in Control, then Employee will be
eligible to receive the benefits provided in paragraph 4(b), under the terms and conditions
set forth in that paragraph.

     “Change of Control” shall be defined as (i) a merger or consolidation in which the
Company is not the surviving entity, except for a transaction the principal purpose of which
is to change the State of the Company’s incorporation; (ii) the sale, transfer or other
disposition of all or substantially all of the assets of the Company in liquidation or
dissolution of the Company; (iii) any reverse merger in which the Company is the surviving
entity but in which securities possessing more than fifty percent (50%) of the total
combined voting power of the Company’s outstanding securities are transferred to a person or
persons different from the persons holding those securities immediately prior to such
merger; (iv) any person or related group of persons (other than the Company or a person
that directly or indirectly controls, is controlled by, or is under common control with, the
Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule
13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total
combined voting power of the Company’s outstanding securities pursuant to a tender or
exchange offer made directly to the Company’s stockholders; or (v) a change in the
composition of the Board over a period of twenty-four (24) consecutive months or less such
that a majority of the Board members (rounded up to the next whole number) ceases, by reason
of one or more contested elections for Board membership, to be comprised of individuals who
either (A) have been Board members continuously since the beginning of such period or (B)
have been elected or nominated for election as Board members during such period by at least
two-thirds of the Board members described in clause (A) who were still in office at the time
such election or nomination was approved by the Board.

     “Constructive Termination” shall mean a resignation of employment within 30 days of the
occurrence of any of the following events which occurs within 6 months following a Change of
Control: (i) a material reduction in Employee’s responsibilities; (ii) a material reduction
in Employee’s base salary, unless such reduction is comparable in percentage to, and is part
of, a reduction in the base salary of all executive officers of the Company; or (iii) a
relocation of Employee’s principal office to a location more than 50 miles from the location
of Employee’s principal office immediately preceding a Change of Control.

 

 

     (d) If (i) Employee remains an employee of the Company after the expiration of the
three year term of this Agreement; and (ii) within 6 months thereafter, Employee resigns as
a result of a material and adverse change in the Company’s business, then Employee shall be
entitled to receive the severance benefits on the terms and conditions specified in
paragraph 4(b) above.

     (e) In the event (i) any payments described in paragraphs 4(b), (c) or (d) above would
be “deferred compensation” subject to Section 409A of the Internal Revenue Code of 1986, as
amended (the “Code”); and (ii) Employee is a “specified employee” (as defined in Code
Section 409A(2)(B)(i)), such payments shall, to the extent required by Code Section 409A, be
delayed for the minimum period and in the minimum manner necessary to avoid the imposition
of the tax required by Code Section 409A.

5. Non-Competition; Proprietary Information and Inventions.

     (a) Proprietary Information and Inventions Agreement. As a condition precedent
to the employment of Employee by the Company, Employee shall execute the Company’s standard
Proprietary Information and Inventions Agreement, attached hereto as Exhibit A.

     (b) Non-Competition Agreement. The Employee agrees that for one (1) year
following the termination of this Agreement by reason of the voluntary termination by the
Employee, without cause on the part of BioCryst, the Employee shall not become the Chief
Financial Officer or become a key executive of another for-profit business enterprise whose
activities are at such time directly competitive with BioCryst.

     (c) Equitable Remedies. Employee acknowledges and recognizes that a violation
of this paragraph by Employee may cause irreparable and substantial damage and harm to
BioCryst or its affiliates, could constitute a failure of consideration, and that money
damages will not provide a full remedy for BioCryst for such violations. Employee agrees
that in the event of his breach of this paragraph, BioCryst will be entitled, if it so
elects, to institute and prosecute proceedings at law or in equity to obtain damages with
respect to such breach, to enforce the specific performance of this paragraph by Employee,
and to enjoin Employee from engaging in any activity in violation hereof.

6. Miscellaneous.

     (a) Entire Agreement. This Agreement, including the exhibits hereto,
constitutes the entire agreement between the parties relating to the employment of the
Employee by BioCryst and there are no terms relating to such employment other than those
contained in this Agreement. No modification or variation hereof shall be deemed valid
unless in writing and signed by the parties hereto. No waiver by either party of any
provision or condition of this Agreement shall be deemed a waiver of similar or dissimilar
provisions or conditions at any time.

     (b) Assignability. This Agreement may not be assigned without prior written
consent of the parties hereto. To the extent allowable pursuant to this Agreement, this
Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto
and their respective executors, administrators, personal representatives, heirs, successors
and assigns.

 

 

     (c) Notices. Any notice or other communication given or rendered hereunder by
any party hereto shall be in writing and delivered personally or sent by registered or
certified mail, postage prepaid, at the respective addresses of the parties hereto as set
forth below.

     (d) Captions. The section headings contained herein are inserted only as a
matter of convenience and reference and in no way define, limit or describe the scope of
this Agreement or the intent of any provision hereof.

     (e) Taxes. All amounts to be paid to Employee hereunder are in the nature of
compensation for Employee’s employment by BioCryst, and shall be subject to withholding,
income, occupation and payroll taxes and other charges applicable to such compensation.

     (f) Governing Law. This Agreement is made and shall be governed by and
construed in accordance with the laws of the State of Alabama without respect to its
conflicts of law principles.

     (g) Date. This Agreement is dated as of May 23, 2011.

     If the foregoing correctly sets forth our understanding, please signify your acceptance of
such terms by executing this Agreement, thereby signifying your assent, as indicated below.

	 	 	 	 	 
	 

	 	Yours very truly,
	 
	 	 	 	 
	 

	 	BIOCRYST PHARMACEUTICALS, INC.
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Jon P. Stonehouse
	 

	 	 	 	 
	 

	 	 	 	Jon P. Stonehouse

President & Chief Executive Officer
	 
	 	 	 	 
	 

	 	 	 	Address:

4505 Emperor Blvd., Suite 200

Durham, NC 27703

     AGREED AND ACCEPTED, as of this 25th  day of May, 2011.

	 	 	 	 	 
	 

	 	By:
	 	/s/ Thomas R. Staab II, CPA
	 

	 	 	 	 
	 

	 	 	 	Thomas R. Staab II, CPA
	 
	 	 	 	 
	 

	 	 	 	Address:

520 Tharps Lane

Raleigh, NC 27703

 

 

Exhibit A

(Proprietary Information and Inventions Agreement)

EMPLOYEE’S PROPRIETARY INFORMATION AND INVENTIONS

AGREEMENT

I, Thomas R. Staab, recognize that BioCryst Pharmaceuticals. Inc., a Delaware corporation
(hereinafter the “Company”, is engaged in a continuous program of research, development, and
product; on respecting its business, present and future, including fields generally related to its
business.

I understand that:

	A.	 	As part of my employment by the Company I will faithfully and diligently serve and endeavor
to further and safeguard the interests of the Company and I recognize that I am expected to
make new contributions and inventions of value to the Company;

	B.	 	My employment creates a relationship of confidence and trust between me and the Company with
respect to any information:

	 	1.	 	Applicable to the business of the Company: or
	 
	 	2.	 	Applicable to the business of any client or customer of the Company which may be made
known to me by the Company or by any client or customer of Company or learned by me during
the period of my employment.

	C.	 	The Company possesses and will continue to possess information that has been created,
discovered, developed, or otherwise become known to the Company (including without limitation
information created, discovered, developed, or made known by me during the period of or
arising out of my employment by the Company) and/or in which property rights have been
assigned or otherwise conveyed to the Company, which information has commercial value in the
business in which the Company is or may be engaged. All of the aforementioned information is
hereinafter called “Proprietary Information.” By way of illustration, but not limitation
Proprietary Information includes trade secrets, processes, formulas, data and know-how,
improvements, inventions, techniques, marketing plans, strategies, forecasts, and customer
lists.
	 
	 	 	In consideration of my employment or continued employment, as the case may be, by the Company
and the compensation received by me from the Company from time to time. I hereby agree as
follows:

	 	1.	 	All Proprietary Information shall be the sole property of the Company and its assigns,
and the Company and its assigns shall be the sole owner of all patents and other rights,
title and interest in connection therewith. I hereby assign to the Company any and all
rights I may have or acquire in such Proprietary Information and/or patents. At all times,
both during my employment by the Company and after its termination, I will keep in
confidence and trust all Proprietary Information, and I will not use or disclose any
Proprietary Information or anything relating to it without the prior written consent of the
Company, except as may be necessary in the ordinary course of performing my duties as an
employee of the Company.
	 
	 	2.	 	I agree that, during the period of my employment by the Company, I will not, without
the Company’s express prior written consent, engage in any employment or consulting other
than for the Company. In the event of the termination of my employment by me or by the
Company for any reason, I will promptly deliver to the Company all documents and data of
any nature pertaining to my work with the Company and I will not take with me any documents
or data of any description or any reproduction of any description containing or pertaining
to any Proprietary Information.

 

 

	 	3.	 	I will promptly and fully disclose to the Company, or any persons designated by it, all
improvements, inventions, formulas, processes, techniques, know-how, and data, whether or
not patentable, copyrightable, or otherwise protectable as property, made or conceived or
reduced to practice or learned by me, either alone or jointly with others, during the period
of my employment by the Company which are related to or useful in the business of the
Company, or result from tasks assigned me by the Company or result from use of premises
owned, leased, or contracted for by the Company (all said improvements, inventions ,
formulas, processes, techniques, know-how, and data shall be collectively hereinafter called
“Inventions”). I agree to keep complete, accurate, and authentic accounts, notes, data, and
records of all Inventions in the manner and form requested by the Company, which accounts,
notes, data, and records shall be and remain the sole property of the Company. I agree to
surrender the same promptly to the Company upon its request or, in the absence of such a
request, upon the termination of my employment by the Company.
	 
	 	4.	 	I agree that all Inventions are and shall be the sole property of the Company and its
assigns, and that the Company and its assigns shall be the sole owner of all patents and
other rights in connection therewith. I hereby assign to the Company any and all rights I
may have or acquire in or to such Inventions and patents. I further agree as to all such
Inventions to assist the Company in every proper way (but at the Company’s expense) to
obtain and from time to time enforce patents, including amendments, extensions, and
continuations of said patents on said Inventions in any and all countries, and to that end
I will execute all documents for use in applying for and for obtaining such patents,
amendments, extensions, and continuations and enforcing same, as the Company may desire,
together with any assignments thereof to the Company or persons designated by it. My
obligation to assist the Company in obtaining and enforcing patents, amendments,
extensions, and continuations for such Inventions in any and all countries shall continue
beyond the termination of my employment, but the Company shall compensate me at a
reasonable rate after such termination for time actually spent by me at the Company’s
request on such assistance.
	 
	 	5.	 	As a matter of record I attach hereto a complete list of all Inventions or improvements
relevant to the subject matter of my employment by the Company which have been conceived,
made, or reduced to practice by me, alone or jointly with others, prior to my engagement by
the Company which I desire to remove from the operation of this Agreement. I covenant that
such list is complete. If no such list is attached to this Agreement, I represent that I
have no such Inventions and improvements at the time of signing this Agreement.
	 
	 	6.	 	I represent that my performance of all of the terms of this Agreement and as an
employee of the Company does not and will not breach any agreement to keep in confidence
Proprietary Information acquired by me in confidence or in trust prior to my employment by
the Company. I have not entered into, and I agree that I will not enter into, any agreement
either written or oral, in conflict herewith.
	 
	 	7.	 	I understand that, as part of the consideration of the offer of employment extended to
me by the Company or of my continued employment by the Company, as the case may be, I will
not bring, have not brought, with me to the Company and I will not use, have not used, in
the performance of my responsibilities at the Company, materials or documents of a former
employer, unless I have obtained written authorization from the former employer for their
possession and use. Accordingly, this is to advise the Company that the only materials
that I will bring to the Company or use in my employment are identified on the attached
sheet (Exhibit A) and, as to each such item, I represent that I have obtained, prior to the
effective date of my employment with the Company, written authorization for their
possession and use in my employment with the Company. I also understand that, in my
employment with the Company, I am not to breach any obligation of confidentiality that I
have to former employers, and I agree that I shall fulfill all such obligations during my
employment with the Company.

 

 

	 	8.	 	This Agreement shall be effective as of the first day of my employment by the Company,
namely: July 1, 2011. I understand and agree that this Agreement is not a contract of
employment and that my employment by the Company is, for all purposes, “at will.”
	 
	 	9.	 	This Agreement shall be binding upon me, my heirs, executors, assigns, administrators,
and other legal representatives and shall inure to the benefit of the Company, its
successors and assigns.

	 	 	 
	DATED: May 25, 2011

	 	Employee: /s/ Thomas R. Staab II
	 
	 	 
	ACCEPTED AND AGREED TO:
	 	 
	 
	 	 
	BIOCRYST PHARMACEUTICALS, INC.
	 	 
	 
	 	 
	BY: /s/ Robert C. Stoner

AS ITS: Vice President of Human Resources
	 	 
	 
	 	 
	 
	 	 
	Dated: May 25, 2011

BioCryst Pharmaceuticals. Inc.

4505 Emperor Blvd., Suite 200

Durham, NC 27703
	 	 

 

 

Dear Sir:

I Thomas R. Staab II propose to bring to my BioCryst employment the following tangible
materials and previously unpublished documents, which materials and documents may be used in my
BioCryst employment:

 X  No materials           
                 See below                            Additional sheets attached

The signature below by a representative of my current or former employer confirms that my continued
possession and use of these materials is authorized.

AUTHORIZATION:

Signature: /s/ Robert C. Stoner

Title: VP HR

Employer: BioCryst Pharmaceuticals

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]